Navigation Links
Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
Date:11/6/2012

DUBLIN, November 6, 2012 Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President: Masayuki Kobayashi), the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies. The data being presented during the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics from November 6 9, 2012 in Dublin, Ireland underscore Taiho's steadfast commitment to improving cornerstone anti-metabolic cancer agents and developing novel molecular targeted therapies that can be used alone or in combination worldwide.

"The data being presented demonstrate Taiho's ability to develop novel molecular targeted agents as well as next generation cytotoxic therapies, and underscore our continued commitment to developing investigational anticancer drugs that have the potential to improve treatment options available to cancer patients," said Masayuki Kobayashi, Taiho Pharmaceutical's president. "Our strategy surrounding innovative research and clinical development reinforces Taiho's pursuit of becoming a top-ten oncology company in the next decade."

Rapid Advancement

Taiho established a foundation of innovative product development 50 years ago, and the Company is committed to achieving efficiencies to effectively yield rapid results. This commitment is best demonstrated by the recent movement of the TAS-102 antitumor agent through preclinical and clinical development. Preclinical results being presented at the EORTC-NCI-AACR Symposium show that TAS-102 exhibited marked tumor growth delay after drug treatment due to FTD incorporation into DNA when evaluated using a well-recognized animal model for breast cancer, and a survival benefit in a colon cancer model.

A Phase II study of TAS-102, conducted in Japan, demonstrated an improvement in overall survival of patients with metastatic
'/>"/>

Contact: Kerry Sinclair
kerry.sinclair@gcihealth.com
310-967-2952
GCI Health
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Medical care presents update on pharmaceutical health services research
2. Scientists use sound waves to levitate liquids, improve pharmaceuticals
3. Pharmica Consulting to Hold HIT Conference for the Pharmaceutical Industry
4. Is it constitutional for states to regulate pharmaceutical gifts and meals to doctors?
5. 5 more pharmaceutical companies join NIH initiative to speed therapeutic discovery
6. Nobel laureate to keynote international pharmaceutical conference at URI
7. MSU invention could help pharmaceutical industry save money
8. Global, common approach to pharmaceutical supply chain integrity the focus of workshop
9. 'EMT Exam Ace' Unveils Free Sample EMT Practice Quizzes
10. DRE Medical Equipment Unveils FX-300+ Surgical Headlight and Light Source
11. CustomerCentric Selling® Unveils New Client Testimonial Videos to Showcase Significant Sales Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dr. Svetlana Gomer, MGS Tewksbury Dental, ... gathered with US Marines on November 14, 2014 for ... the Toys for Tots Literacy Program. This year’s ... books and audio books for the Toys for Tots ... Christmas. It represents another major strike in the battle ...
(Date:12/24/2014)... 2014 The report offers details on ... various market dynamics such as the key trends, the ... wait time for U.S. sports medicine, the impact of ... the challenges faced by the market. , Browse report ... The report also provides an overview of the global ...
(Date:12/24/2014)... Verde Pointe Dental Associates 2014 Ugly Holiday ... years homemade Christmas sweater lit up, but this years overall ... is Tandy Wilson for the second year in a row. ... Kimmerling DDS. "She took pictures of the entire staff and ... , "Every year I enjoy stopping by the dental ...
(Date:12/24/2014)... Dental implants benefit millions of individuals ... They offer the strongest and most secure hold for ... of tooth replacement. They will never slip out of ... for support, and they prevent the jaw from shrinking ... they are not suitable candidates for dental implants because ...
(Date:12/24/2014)... 24, 2014 Attorneys handling talcum powder ... update to their website, the Talcum Powder Ovarian ... talcum powder class action lawsuits and ovarian cancer claims. ... ovarian cancer updates at their website, which serves as ... ovarian cancer claims are not the same as class ...
Breaking Medicine News(10 mins):Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3Health News:Sports Medicine Market Report 2014: Global Industry Analysis, Share, Size, Trends, Growth and Forecast report 2Health News:Verde Pointe Dental Associates Announces the 2014 Ugly Sweater Holiday Contest Winner 2Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 4
... University of Texas, offer some valuable advice on how to ... essential for healthy bones and teeth, and helps prevent osteoporosis ... helps the body produce vitamin D.// Just10 to 15 minutes ... But be warned many factors can reduce sunlight exposure, such ...
... with transplanted hearts from female donors, the proof is the ... at least somewhat by recruiting cells from elsewhere in the ... or dead, they could not be replaced or repaired by ... is found only in men, researchers determined that the female ...
... oxygen therapy at home reduces hospitalisation in those with lung ... the effects of oxygen on 200 patients with smoker's lungs// ... was begun in an outpatient clinic, then continued at home. ... a day, proved to be beneficial. The patients had a ...
... study, a combined scan identifies unstable areas of plaque in ... the future. Fatty deposits, known as plaque, set the scene ... - begins many years before any symptoms occur.// The plaque ... a clot which will then cause a heart attack. ...
... recent study by researchers at the University of Texas, have ... cancer.Omega-3 fatty acids, which are found in fish oil, have ... that the omega-3s block a molecule called protein kinase C ... division. ,In this study, genetically-modified mice, which produce ...
... suggested by researchers to relieve chronic headaches. Botox injections ... not relieved by conventional medication. Botox is shorthand for ... to man. However, it does have some benign uses ... out wrinkles in cosmetic surgery. Now researchers at the ...
Cached Medicine News:
(Date:12/24/2014)... BUFFALO, N.Y. , Dec. 24, 2014 ... been dosed with KX2-361 at Roswell Park Cancer Institute. ... a small molecule drug that has shown potent inhibitory ... lines, including those that are resistant to Temozolomide (T98G), ... malignant glioma. In a well-established brain tumor mouse model, ...
(Date:12/24/2014)... and FARMINGTON, Conn. , Dec. ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of 2,050,000 shares of its common stock ... of its common stock.  Funds under the management ...
(Date:12/24/2014)... DIEGO , Dec. 23, 2014 ResMed (NYSE: ... significant patent infringement action against Chinese medical device manufacturer BMC ... (ITC) ruled today that BMC,s masks listed below infringe ResMed,s ... or selling these masks in the United States ... iVolve N2 nasal mask , Willow nasal pillows mask ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... FRANKFORT, Ky., Oct. 7, 2011 The Consumer ... the Kentucky General Assembly to adopt a new ... and abuse, the Meth Offender Registry Block List. ... from purchasing medicines containing pseudoephedrine (PSE) –medicines like ...
... Pharmaceuticals, Inc. (NYSE: WPI ) today confirmed ... an Abbreviated New Drug Application (ANDA) with the U.S. ... Morphine Sulfate and Naltrexone Hydrochloride Extended-release Capsules 30 mg/1.2 ... mg, and 100 mg/4 mg.  Watson,s Morphine Sulfate and ...
Cached Medicine Technology:Consumer Group Advances Alternative to Prescription Mandate 2Consumer Group Advances Alternative to Prescription Mandate 3Watson Confirms EMBEDA(R) Patent Challenge 2Watson Confirms EMBEDA(R) Patent Challenge 3
0.5 mm wide x 1.5 mm long. Angled 20 degrees. Octagonal handle....
2 mm wide curved tip. Round handle....
8 mm downcutting Royce blade. Angled shaft. 60 mm from angle to tip....
3 mm disposable Lance blade. Can fit in to the N0521 Storz handle....
Medicine Products: